Consensus Novartis AG London S.E.

Equities

0QM7

CH0038459415

Delayed London S.E. Other stock markets 16:59:30 21/05/2018 BST			5-day change	1st Jan Change
76.86 ^CHF	-1.00%		-0.77%	-.--%

06-24	Foreign banks target Switzerland after UBS takeover of Credit Suisse	RE
06-24	NOVARTIS AG : Barclays reaffirms its Sell rating	ZD

Evolution of the average Target Price on Novartis AG

Price target over the last 5 years

History of analyst recommendation changes

d8ee7288790ac.jKuGLHUm1oMGzhVeJCUzih7xjrMi_Wgezw5WsfESLBY.6tvVdgZikelA41IIUWF9zzOe2d1Kuzh5gX4gx6JIQHLT-NV9PxOYwE_jfg~5683bbaafb6f8c535bc95e0640ba3749

Analyst Recommendations on Novartis AG

NOVARTIS AG : Barclays reaffirms its Sell rating	06-24	ZD
NOVARTIS AG : JP Morgan reiterates its Neutral rating	06-11	ZD
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation	06-06	MT
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists	06-06	RE
NOVARTIS AG : Deutsche Bank maintains a Buy rating	06-05	ZD
Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation	06-04	MT
NOVARTIS AG : JP Morgan remains Neutral	06-03	ZD
NOVARTIS AG : Buy rating from Goldman Sachs	06-03	ZD
NOVARTIS : UBS reiterates buy recommendation after ASCO	06-03	CF
NOVARTIS AG : UBS gives a Buy rating	06-03	ZD
NOVARTIS AG : UBS reiterates its Buy rating	05-31	ZD
NOVARTIS AG : Jefferies remains its Buy rating	05-31	ZD
Goldman Sachs Starts Novartis With Buy Rating, $120 Price Target	05-30	MT
NOVARTIS AG : From Sell to buy Rating by Goldman Sachs	05-30	ZD
NOVARTIS AG : Deutsche Bank remains its Buy rating	05-24	ZD
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating	05-23	MT
NOVARTIS AG : Berenberg remains Neutral	05-23	ZD
NOVARTIS AG : UBS maintains a Buy rating	05-06	ZD
NOVARTIS AG : Receives a Buy rating from Jefferies	04-26	ZD
BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	04-24	MT
NOVARTIS AG : UBS reaffirms its Buy rating	04-24	ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating	04-24	ZD
NOVARTIS AG : JP Morgan remains Neutral	04-24	ZD
NOVARTIS : 2024 has started on a strong note; guidance upgraded	04-23
NOVARTIS AG : JP Morgan gives a Neutral rating	04-23	ZD

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

107.2 USD

Average target price

110.3 USD

Spread / Average Target

+2.88%

High Price Target

131.7 USD

Spread / Highest target

+22.84%

Low Price Target

84.2 USD

Spread / Lowest Target

-21.47%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novartis AG

BARCLAYS	Emily Field
JPMORGAN	Richard Vosser
AlphaValue
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
Baader Bank
UBS	Matthew Weston
GOLDMAN SACHS	James Quigley
JEFFERIES	Peter Welford
Berenberg Bank
BERENBERG	Kerry Holford
BMO Capital
DZ BANK	Elmar Kraus
Kepler Capital Markets
Societe Generale
Redburn
Stifel Nicolaus
BNP Paribas
MORGAN STANLEY	Mark Purcell
Barrington Research
Credit Suisse
International Strategy & Investment Group
Morningstar
ODDO BHF
DA Davidson
Zacks Equity Research
Bank of America Securities/Merrill Lynch
BERNSTEIN RESEARCH	Wimal Kapadia
Kepler Cheuvreux
Wolfe Research
AltaCorp Capital
DEUTSCHE BANK	Emmanuel Papadakis
HSBC
Exane BNP Paribas
Bryan, Garnier & Co.
Deutsche Bank Securities
Moody's Investors Service
Dundee
Exane BNP
Bernstein
Argus
Cowen
BRYAN GARNIER	Eric Le Berrigaud
LIBERUM CAPITAL	Graham Doyle
BANK OF AMERICA (BOFA)	Graham Parry

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar